Dr. Gupta Discusses Adjuvant Immunotherapy in Kidney Cancer

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses adjuvant immunotherapy in kidney cancer.

There is a lot of interest in adjuvant therapy in kidney cancer, Gupta says. Trials with immunotherapy are being compared with placebo, but Gupta says that these agents should probably be compared with sunitinib (Sutent), if it gains FDA approval.

Additionally, Gupta says that patients with non-clear cell kidney cancer should be included in these adjuvant trials as well.